GlobeNewswire by notified

UPM Annual Report 2022, Corporate Governance Statement and Remuneration Report published

Share

UPM-Kymmene Corporation        Annual Financial Report                3 March 2023 at 9:15 EET

UPM Annual Report 2022, Corporate Governance Statement and Remuneration Report published

UPM's Annual Report 2022 has been published online at www.upm.com and www.upm.fi. The Annual Report including the company's Financial Statements and the Report of the Board of Directors for the period 1 January - 31 December 2022 is available in English and Finnish on the corporate website. In accordance with the European Single Electronic Format (ESEF) reporting requirements, the Financial Statements and Report of the Board of Directors for the year 2022 have also been published in xHTML format. In line with the ESEF requirements, the primary statements and notes of the consolidated financial statements have been labelled with XBRL tags. XBRL tags have not been subject to audit and have not been assured by auditors.

UPM has also published its Corporate Governance Statement and the Remuneration Report for the financial year 2022. The Remuneration Report for governing bodies introduces the remuneration of the directors and the President and CEO. The Remuneration Report 2022 will be presented at the Annual General Meeting 2023 on 12 April 2023. The Statement and the Remuneration Report are available on the corporate website at www.upm.com/governance (the Investors section under Governance).

All material information has been integrated into this one, third-party assured entirety and UPM does not publish separate sustainability report.

For UPM, 2022 was a pivotal year. Our annual sales and earnings were at an all-time high. All our businesses succeeded despite the extraordinary events happening in the world around us. Our transformative growth projects also progressed as planned towards the finish line. The annual report provides comprehensive information on our transformation as a frontrunner in biomaterials and our progress towards the 2030 responsibility targets. We launched the UPM Forest Action programme, which will run until 2030, and we made biodiversity into a separate focus area with own targets. In 2022, our energy-related CO2 emissions decreased by 11% compared to the previous year. Our purpose is to create a future beyond fossils with everyday actions for the future.

The Annual Report, the Statement and the Remuneration Report can be downloaded as PDF files in English and Finnish and the Financial Statements and the Report of the Board of Directors as xHTML file and they are also attached to this release.

The printed Annual Report will be published on the week beginning on 13 March. The printed report can be ordered at www.upm.com/investors/subscribe-to-the-annual-report/ .

Attachments
Annual report 2022
Financial Statements and Report of the Board of Directors for the year 2022 in xHTML format
Corporate Governance Statement 2022
The Remuneration Report 2022

UPM-Kymmene Corporation
Pirkko Harrela
Executive Vice President, Stakeholder Relations

UPM, Media Relations
Mon-Fri 9:00-16:00 EET
Tel. +358 40 588 3284
media@upm.com

UPM
We deliver renewable and responsible solutions and innovate for a future beyond fossils across six business areas: UPM Fibres, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers and UPM Plywood. As the industry leader in responsibility, we are committed to the UN Business Ambition for 1.5°C and the science-based targets to mitigate climate change. We employ 17,200 people worldwide and our annual sales are approximately EUR 11.7 billion. Our shares are listed on Nasdaq Helsinki Ltd. UPM Biofore – Beyond fossils. www.upm.com

Follow UPM on Twitter | LinkedIn | Facebook | YouTube | Instagram | #UPM #biofore #beyondfossils

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities21.3.2023 16:00:00 CET | Press release

Company Announcement No. 16/2023 Copenhagen, 21 March 2023 Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities 1. Information on the person discharging managerial responsibilities/person closely associated a) Name Niels Frederiksen 2. Reason for the notification a) Position/title CEO and member of the Executive Management b) Initial notification/amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Scandinavian Tobacco Group A/S b) LEI code 5299003KG4JS99TRML67 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Shares DK0060696300 – STG b) Nature of the transaction Grant of shares due to vesting of performance share

Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation21.3.2023 15:48:10 CET | Press release

Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulation Sandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competition Basel, March 21, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that the US Food and Drug Administration (FDA) approved a citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz® (adalimumab-adaz) injection. The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira®* (adalimumab), including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.1 Sandoz

Articles of Association for RTX A/S21.3.2023 15:28:54 CET | Press release

Nørresundby, Denmark, 21 March 2023 Announcement no. 11/2023 Articles of Association for RTX A/S as adopted at the Annual General Meeting on 26 January 2023 and finally adopted at the extraordinary general meeting on 10 March 2023 (cf. company announcement 10/2023) has been registered and published. The Articles of Association are available at the company’s website www.rtx.dk under: Governance => Articles of Association. Questions and further information: CEO Peter Røpke, tel: +45 96 32 23 00 Attachment RTX A-S - Articles of Association 10 March 2023

Vedtægter for RTX A/S21.3.2023 15:28:54 CET | pressemeddelelse

Nørresundby, den 21. marts 2023 Selskabsmeddelelse nr. 11/2023 Vedtægter for RTX A/S som vedtaget på RTX’s ordinære generalforsamling 26. januar 2023 og endeligt vedtaget på selskabets ekstraordinære generalforsamling 10. marts 2023 (jf. selskabsmeddelelse 10/2023) er blevet registreret og offentliggjort. Vedtægterne er tilgængelige på selskabets hjemmeside www.rtx.dk under: Governance => Vedtægter. Spørgsmål og yderligere oplysninger: CEO Peter Røpke, tlf: +45 96 32 23 00. Vedhæftet fil RTX A-S - vedtægter pr. 10. marts 2023